Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Neumora Therapeutics's share price for the quarter that ended in Mar. 2024 was $13.75. Neumora Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 159.36 Mil. Therefore, Neumora Therapeutics's market cap for the quarter that ended in Mar. 2024 was $2,191.17 Mil.
Neumora Therapeutics's quarterly market cap
increased
from Sep. 2023 ($2,144.00 Mil) to Dec. 2023 ($2,708.09 Mil) but then
declined
from Dec. 2023 ($2,708.09 Mil) to Mar. 2024 ($2,191.17 Mil).
Neumora Therapeutics's annual market cap
stayed the same
from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then
increased
from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($2,708.09 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Neumora Therapeutics's Enterprise Value for Today is $1,129.10 Mil.
Neumora Therapeutics Market Cap Historical Data
The historical data trend for Neumora Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neumora Therapeutics's Market Cap
For the Biotechnology subindustry, Neumora Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neumora Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Neumora Therapeutics's Market Cap falls into.
Neumora Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Neumora Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neumora Therapeutics (NAS:NMRA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Neumora Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Neumora Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Neumora Therapeutics (Neumora Therapeutics) Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMRA has been successfully added to your 